Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis

Arnold L. Smith*, Gregory Redding, Carl Doershuk, Donald Goldmann, Edmond Gore, Bettina Hilman, Melvin Marks, Richard Moss, Bonnie Ramsey, Thomas Roblo, Robert H. Schwartz, Mary J. Thomassen, Judy Williams-Warren, Allan Weber, Robert W. Wilmott, H. David Wilson, Ram Yogev

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

115 Scopus citations

Abstract

We sought to define objective indicators of the resolution of Pseudomonas aeruginosa endobronchial infection in patients with cystic fibrosis. We prospectively studied 75 patients admitted for treatment of a pulmonary exacerbation and quantitated sputum bacterial density, DNA content, and the concentration of albumin and total protein in sputum, and compared these values with clinical evaluation. Eleven of the 75 patients had systemic signs, fever, and leukocytosis, which we arbitrarily defined as due to endobronchial infection. At the end of hospitalization, these 11 patients were afebrile, had peripheral leukocyte counts in the normal range, and were judged improved. Sputum P. aeruginosa density, DNA content, and total protein content on admission were similar in the two illness groups. Hospitalization and parenteral antibiotic administration for an average of 14.6 days were associated with improved pulmonary function in all 75 subjects (P values for forced vital capacity, forced expiratory volume at 1 second, and peak expiratory flow rate were all 7.80 CFU/g on admission to 105.96 CFU/g; P

Original languageEnglish (US)
Pages (from-to)547-554
Number of pages8
JournalThe Journal of pediatrics
Volume112
Issue number4
DOIs
StatePublished - Apr 1988

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis'. Together they form a unique fingerprint.

Cite this